Daniel  Raskas net worth and biography

Daniel Raskas Biography and Net Worth

SVP of Danaher
As Senior Vice President, Corporate Development, Daniel Raskas leads mergers and acquisitions in partnership with Bill King and oversees investment activity, including identification, valuation, due diligence, contract strategy and negotiations.

Daniel joined Danaher in 2004, originally serving as Vice President of Corporate Development, and was promoted to his current role in 2010. Throughout his tenure, he has led business development across the company and overseen a number of major acquisitions, including Beckman Coulter, Pall and Cytiva.

Before joining Danaher, Daniel was a partner at Thayer Capital Partners, a private equity firm focused on buyout and growth equity investments in the middle market. He also served as an associate at Arnold & Porter LLP for several years, where he specialized in transactional work including M&A and public offerings.

Daniel received a B.A. in Government from Harvard College, an M.B.A. from Columbia University School of International and Public Affairs, and a J.D. from Harvard Law School.

What is Daniel Raskas' net worth?

The estimated net worth of Daniel Raskas is at least $10.07 million as of February 26th, 2024. Mr. Raskas owns 38,102 shares of Danaher stock worth more than $10,065,786 as of July 24th. This net worth approximation does not reflect any other investments that Mr. Raskas may own. Learn More about Daniel Raskas' net worth.

How do I contact Daniel Raskas?

The corporate mailing address for Mr. Raskas and other Danaher executives is 2200 PENNSYLVANIA AVE. N.W SUITE 800W, WASHINGTON DC, 20037. Danaher can also be reached via phone at (202) 828-0850 and via email at [email protected]. Learn More on Daniel Raskas' contact information.

Has Daniel Raskas been buying or selling shares of Danaher?

Daniel Raskas has not been actively trading shares of Danaher during the past quarter. Most recently, Daniel Raskas sold 23,757 shares of the business's stock in a transaction on Monday, February 26th. The shares were sold at an average price of $252.00, for a transaction totalling $5,986,764.00. Following the completion of the sale, the senior vice president now directly owns 38,102 shares of the company's stock, valued at $9,601,704. Learn More on Daniel Raskas' trading history.

Who are Danaher's active insiders?

Danaher's insider roster includes Rainer Blair (EVP), Daniel Comas (EVP), Georgeann Couchara (SVP), William Daniel (EVP), Brian Ellis (SVP), Linda Filler (Director), Jose-Carlos Gutierrez-Ramos (SVP), Linda Hefner (Director), Jennifer Honeycutt (EVP), Thomas Joyce, Jr. (CEO), William King (SVP), Angela Lalor (SVP), Angela Lalor (SVP), Teri List (Director), Walter Lohr (Director), Robert Lutz (CAO), Matthew McGrew (CFO), Mitchell Rales (Chairman), Daniel Raskas (SVP), John Schwieters (Director), Alan Spoon (Director), Raymond Stevens (Director), Joakim Weidemanis (EVP), and Elias Zerhouni (Director). Learn More on Danaher's active insiders.

Are insiders buying or selling shares of Danaher?

In the last twelve months, insiders at the conglomerate sold shares 16 times. They sold a total of 229,662 shares worth more than $58,354,751.67. The most recent insider tranaction occured on May, 16th when CEO Rainer Blair sold 9,005 shares worth more than $2,386,325.00. Insiders at Danaher own 11.1% of the company. Learn More about insider trades at Danaher.

Information on this page was last updated on 5/16/2024.

Daniel Raskas Insider Trading History at Danaher

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/26/2024Sell23,757$252.00$5,986,764.0038,102View SEC Filing Icon  
7/28/2023Sell11,213$260.65$2,922,668.4538,288View SEC Filing Icon  
5/31/2023Sell19,847$228.50$4,535,039.5038,673View SEC Filing Icon  
11/26/2021Sell12,300$325.33$4,001,559.00View SEC Filing Icon  
10/23/2020Sell28,389$234.50$6,657,220.5038,850View SEC Filing Icon  
5/8/2020Sell37,082$164.09$6,084,785.3819,723View SEC Filing Icon  
11/16/2017Sell37,870$93.33$3,534,407.10View SEC Filing Icon  
2/26/2016Sell4,656$89.00$414,384.0017,786View SEC Filing Icon  
2/26/2015Sell4,179$87.79$366,874.41View SEC Filing Icon  
2/20/2015Sell56,000$87.03$4,873,680.00View SEC Filing Icon  
5/1/2014Sell11,158$73.48$819,889.8418,368View SEC Filing Icon  
10/18/2013Sell20,000$71.99$1,439,800.00View SEC Filing Icon  
7/24/2013Sell20,000$67.54$1,350,800.00View SEC Filing Icon  
See Full Table

Daniel Raskas Buying and Selling Activity at Danaher

This chart shows Daniel Raskas's buying and selling at Danaher by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Danaher Company Overview

Danaher logo
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
Read More

Today's Range

Now: $266.38
Low: $261.60
High: $268.27

50 Day Range

MA: $254.84
Low: $239.25
High: $267.98

2 Week Range

Now: $266.38
Low: $182.09
High: $272.98

Volume

909,926 shs

Average Volume

2,889,696 shs

Market Capitalization

$197.31 billion

P/E Ratio

45.15

Dividend Yield

0.43%

Beta

0.83